Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.

2.
3.

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.

Clin Ther. 2010 Aug;32(9):1565-77. doi: 10.1016/j.clinthera.2010.08.009. Review.

PMID:
20974315
4.

The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.

Hartwell D, Cooper K, Frampton GK, Baxter L, Loveman E.

Health Technol Assess. 2014 Oct;18(65):i-xxii, 1-202. doi: 10.3310/hta18650. Review.

5.

Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.

Perry CM, Jarvis B.

BioDrugs. 2002;16(3):213-7. Review.

PMID:
12102649
6.
7.

Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.

Keam SJ, Cvetković RS.

BioDrugs. 2009;23(1):63-8. doi: 10.2165/00063030-200923010-00007. Review.

PMID:
19344193
8.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
9.

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.

Singal AK, Jampana SC, Anand BS.

Dig Dis Sci. 2011 Aug;56(8):2221-6. doi: 10.1007/s10620-011-1765-0. Epub 2011 Jun 4. Review.

PMID:
21643737
10.

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

Rajender Reddy K, Modi MW, Pedder S.

Adv Drug Deliv Rev. 2002 Jun 17;54(4):571-86. Review.

PMID:
12052715
11.
12.

Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.

Baker DE.

Rev Gastroenterol Disord. 2003 Spring;3(2):93-109. Review.

PMID:
12776006
13.
14.

Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.

Hauser G, Awad T, Thorlund K, Štimac D, Mabrouk M, Gluud C.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005642. doi: 10.1002/14651858.CD005642.pub3. Review.

PMID:
24585451
15.
16.

Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.

Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, Mills EJ.

Clin Infect Dis. 2013 Apr;56(7):961-7. doi: 10.1093/cid/cis1031. Epub 2012 Dec 12. Review.

PMID:
23243171
17.

Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison.

Andersohn F, Claes AK, Kulp W, Mahlich J, Rockstroh JK.

BMC Infect Dis. 2016 Jan 11;16:10. doi: 10.1186/s12879-015-1311-3. Review.

18.

Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.

Iorio A, Marchesini E, Awad T, Gluud LL.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004888. doi: 10.1002/14651858.CD004888.pub2. Review.

PMID:
20091566
19.

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.

Fried MW, Hadziyannis SJ.

Semin Liver Dis. 2004;24 Suppl 2:47-54. Review.

PMID:
15346246
20.

Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review.

Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R.

Ann Intern Med. 2013 Jan 15;158(2):114-23. Review.

PMID:
23437439

Supplemental Content

Support Center